A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Invasion that Showed Favorable Prognosis after Combined External Radiation Therapy and Sorafenib Therapy |
Namyoung Paik1, Dong Hyun Sinn1, Hee Chul Park2, Woo Kyung Jeong3, Min Sun Kim1, Ji Hye Kim1, Bumhee Yang1 |
1Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea 2Departments of Radio-oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea 3Departments of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine,Seoul, Korea |
Correspondence:
Dong Hyun Sinn, Email: dh.sinn@samsung.com |
|
Abstract |
A prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal
that the median survival is 2 to 4 months without treatment. Sorafenib, the standard regimen of
advanced HCC, can prolong median survival only 1.5 months. A 50-year-old man with a history
of chronic hepatitis B was diagnosed advanced HCC with PVTT. By a multidisciplinary medical
team approach, the combination of 3-demensional conformal radiation therapy with sequential
sorafenib was challenged. 4 months after initiation of treatment, he achieved partial response
as modified response evaluation criteria in solid tumors criteria. Sorafenib was continued so
far, and stable disease has been maintained up to now, without significant adverse effect. |
Key Words:
Hepatocellular carcinoma; Sorafenib; Radiation therapy |
NULL |
|